Enzyme Replacement Therapy for Gaucher Disease: Skeletal Responses to Macrophage-targeted Glucocerebrosidase
1 Department of Radiology, Massachusetts General Hospital, Boston
2 Department of Orthopedic Surgery, Massachusetts General Hospital, Boston
3 Biometry and Field Studies Branch, National Institute of Neurological Disorders and Stroke, Clinical Center, National Institutes of Health, Bethesda, MD
4 Department of Medicine, Massachusetts General Hospital, Boston
5 Diagnostic Radiology Department, Clinical Center, National Institutes of Health, Bethesda, MD
6 Developmental and Metabolic Neurology Branch, Clinical Center, National Institutes of Health, Bethesda, MD
Objectives. Reversal of the hematologic and visceral abnormalities characteristic of Gaucher disease, the most common lipid storage disorder, with biweekly infusions of macrophage-targeted glucocerebrosidase (glucosylceramidase) is well documented. The extent to which the skeleton responds to enzyme replacement therapy has not been systematically investigated.
Methods. To assess the skeletal response to enzyme replacement therapy, we treated 12 patients with type 1 Gaucher disease, who had intact spleens, with macrophage-targeted glucocerebrosidase. The initial dose of enzyme was 60 U/kg body weight every 2 weeks for 24 months, followed by reduction in dosage to 30 and then 15 U/kg body weight every 2 weeks, each for 9 months.
Results. The lipid composition of bone marrow, determined by direct chemical analysis, began to improve after 6 months of treatment at a time when noninvasive imaging studies showed no significant changes. By 42 months, improvement in marrow composition was demonstrable on all noninvasive, quantitative imaging modalities (magnetic resonance score, quantitative xenon scintigraphy, and quantitative chemical shift imaging) used in this study. Quantitative chemical shift imaging, the most sensitive technique, demonstrated a dramatic normalization of the marrow fat content in all patients. Net increases in either cortical or trabecular bone mass, as assessed by combined cortical thickness measurements and dual-energy quantitative computed tomography, respectively, occurred in 10 patients.
Conclusions. Prolonged treatment over 3
years with macrophage-targeted glucocerebrosidase produces objective reversal of disease in both the axial and appendicular skeleton in patients with Gaucher disease. Marked improvement occurs in marrow composition and bone mass in both children and adults.
Accepted on December 29, 1994
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  R. F. DeMayo, A. H. Haims, M. C. McRae, R. Yang, and P. K. Mistry Correlation of MRI-Based Bone Marrow Burden Score with Genotype and Spleen Status in Gaucher's Disease Am. J. Roentgenol., July 1, 2008; 191(1): 115 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schmitz, L. W. Poll, and S. v. Dahl Therapy of adult Gaucher disease Haematologica, February 1, 2007; 92(2): 148 - 152. [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Fost, C. E. M. Hollak, J. E. M. Groener, J. M. F. G. Aerts, M. Maas, L. W. Poll, M. G. Wiersma, D. Haussinger, S. Brett, N. Brill, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood, August 1, 2006; 108(3): 830 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Wenstrup, L. Bailey, G. A. Grabowski, J. Moskovitz, A. E. Oestreich, W. Wu, and S. Sun Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy Blood, September 1, 2004; 104(5): 1253 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maas, C. van Kuijk, J. Stoker, C. E. M. Hollak, E. M. Akkerman, J. F. M. G. Aerts, and G. J. den Heeten Quantification of Bone Involvement in Gaucher Disease: MR Imaging Bone Marrow Burden Score as an Alternative to Dixon Quantitative Chemical Shift MR Imaging--Initial Experience Radiology, November 1, 2003; 229(2): 554 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mariani, M. Filocamo, F. Giona, G. Villa, A. Amendola, P. Erba, F. Buffoni, F. Copello, A. Pierini, F. Minichilli, et al. Severity of Bone Marrow Involvement in Patients with Gaucher's Disease Evaluated by Scintigraphy with 99mTc-Sestamibi J. Nucl. Med., August 1, 2003; 44(8): 1253 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Larsen, S. A. Connolly, and A. E. Rosenberg Case 20-2003 - A Nine-Year-Old Girl with Hepatosplenomegaly and Pain in the Thigh N. Engl. J. Med., June 26, 2003; 348(26): 2669 - 2677. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Desnick, R. Brady, J. Barranger, A. J. Collins, D. P. Germain, M. Goldman, G. Grabowski, S. Packman, and W. R. Wilcox Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy Ann Intern Med, February 18, 2003; 138(4): 338 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maas, C. E. M. Hollak, E. M. Akkerman, J. M. F. G. Aerts, J. Stoker, and G. J. Den Heeten Quantification of Skeletal Involvement in Adults with Type I Gaucher's Disease: Fat Fraction Measured by Dixon Quantitative Chemical Shift Imaging as a Valid Parameter Am. J. Roentgenol., October 1, 2002; 179(4): 961 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Maas, L W Poll, and M R Terk Imaging and quantifying skeletal involvement in Gaucher disease Br. J. Radiol., May 24, 2002; 75(90001): A13 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L W Poll, M Maas, M R Terk, M Roca-Espiau, B Bembi, G Ciana, and N J Weinreb Response of Gaucher bone disease to enzyme replacement therapy Br. J. Radiol., May 24, 2002; 75(90001): A25 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Bembi, G Ciana, E Mengel, M R Terk, C Martini, and R J Wenstrup Bone complications in children with Gaucher disease Br. J. Radiol., May 24, 2002; 75(90001): A37 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Mankin, D. I. Rosenthal, and R. Xavier Gaucher Disease : New Approaches to an Ancient Disease J. Bone Joint Surg. Am., May 1, 2001; 83(5): 748 - 763. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. P. MIRANDA, X. HE, C. M. SIMONARO, S. GATT, A. DAGAN, R. J. DESNICK, and E. H. SCHUCHMAN Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology FASEB J, October 1, 2000; 14(13): 1988 - 1995. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Elstein, A. Abrahamov, I. Hadas-Halpern, A. Zimran, J. Charrow, J. A. Esplin, P. Kaplan, E. H. Kolodny, G. M. Pastores, C. R. Scott, et al. Recommendations for Diagnosis, Evaluation, and Monitoring of Patients With Gaucher Disease Arch Intern Med, June 14, 1999; 159(11): 1254 - 1255. [Full Text] [PDF]
|
|
|
|
|
|
B. Friedman, K. Vaddi, C. Preston, E. Mahon, J. R. Cataldo, and J. M. McPherson A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived beta -Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease Blood, May 1, 1999; 93(9): 2807 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rosenberg, W. Kingma, M. A. Fitzpatrick, and S. M. Richards Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration Blood, March 15, 1999; 93(6): 2081 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Charrow, J. A. Esplin, T. J. Gribble, P. Kaplan, E. H. Kolodny, G. M. Pastores, C. R. Scott, R. S. Wappner, N. J. Weinreb, and J. S. Wisch Gaucher Disease: Recommendations on Diagnosis, Evaluation, and Monitoring Arch Intern Med, September 14, 1998; 158(16): 1754 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Brady, G. J. Murray, K. L. Oliver, S. F. Leitman, M. C. Sneller, T. A. Fleisher, N. W. Barton, and Collaborators Management of Neutralizing Antibody to Ceredase in a Patient With Type 3 Gaucher Disease Pediatrics, December 1, 1997; 100(6): e11 - e11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ponce, J. Moskovitz, and G. Grabowski Enzyme Therapy in Gaucher Disease Type 1: Effect of Neutralizing Antibodies to Acid beta -Glucosidase Blood, July 1, 1997; 90(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
